MEDILINK
Live / Registered — Registered (as of 14 May 2024)
What this means for you
Registered since 14 May 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97230276
- Registration number
- 7388604
- Mark type
- Word mark
- Filed
- 20 Jan 2022
- Published for opposition
- 13 Jun 2023
- Registered
- 14 May 2024
- Attorney of record
- Timothy T. Wang
Goods and services
- Class 042 — Scientific and technological services: Biochemical research and development; Biomedical research services; Biotechnology research; Chemical research; Chemical research and analysis; Chemistry consultation; Development and test of chemical production methods; Development of pharmaceutical preparations and medicines; Medical and scientific research, namely, conducting clinical trials for others; Pharmaceutical research and development; Professional consulting services and advice about agricultural chemistry; Research and development in the field of antibody-drug conjugates; Research and development in the field of antibody conjugates; Research and development in the field of drug conjugates; Research and development in the pharmaceutical and biotechnology fields; Research and development services in the field of antibodies; Research in the field of chemistry; Scientific research for medical purposes in the area of cancerous diseases; Scientific research in the nature of conducting clinical trials for others; Technology research in the field of pharmaceutical preparations and medical instruments; Testing of chemicals; Testing of cosmetics; Testing of pharmaceuticals
Owner
- MediLink Therapeutics(Suzhou)Co.,Ltd., Suzhou, Jiangsu, CN
- MediLink Therapeutics(Suzhou)Co.,Ltd., Suzhou, Jiangsu, CN
- MediLink Therapeutics(Suzhou)Co.,Ltd., Suzhou, Jiangsu, CN
Prosecution history
- 14 May 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 14 May 2024 — REGISTERED-PRINCIPAL REGISTER
- 12 Apr 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 11 Apr 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 19 Mar 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 19 Mar 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 19 Mar 2024 — ASSIGNED TO LIE
- 31 Oct 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 20 Sept 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 20 Sept 2023 — NON-FINAL ACTION E-MAILED
- 20 Sept 2023 — SU - NON-FINAL ACTION - WRITTEN
- 28 Aug 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 22 Aug 2023 — USE AMENDMENT FILED
- 28 Aug 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 22 Aug 2023 — TEAS STATEMENT OF USE RECEIVED